1 2 4 5 a r t I C l e S Schizophrenia is a severe and persistent psychiatric condition that affects almost 1% of the world's population 1,2 . In some patients with schizophrenia, typical and atypical antipsychotic drugs produce complete remission of psychotic symptoms. However, about 30% of patients are considered treatment resistant and will continue to experience psychotic and other symptoms despite the optimal use of available antipsychotic medications 3, 4 . Over the last 40 years, a variety of adjunctive treatments have been used to enhance the response to antipsychotic medications 5 . Among these, preclinical 6-8 and clinical 9-11 studies suggest that drugs such as valproate, one of whose functions is to act as a nonspecific histone deacetylase (HDAC) inhibitor 12, 13 , are efficacious when given chronically in combination with atypical antipsychotic drugs, including clozapine, olanzapine and risperidone. HDACs remove acetyl groups from lysine residues in the N-terminal tails of core histones, which shifts the balance toward chromatin condensation and thereby silences gene expression 14, 15 . As yet, the molecular mechanism that integrates a better response to antipsychotics with pharmacological modulation of HDAC function remains unknown.
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Monoaminergic neurotransmitters are heavily involved in the pathophysiology of schizophrenia and other psychotic disorders.
Atypical antipsychotic drugs all have in common a high affinity for the serotonin 5-HT 2A receptor (5HT2A), as well as a modest affinity for the dopamine D2 receptor 16, 17 . Hallucinogenic drugs, such as lysergic acid diethylamide (LSD), psilocybin and mescaline, recruit specific 5HT2A-mediated signaling pathways to affect behavior in humans and rodents 18, 19 . These findings are consistent with the implication of the 5HT2A receptor in the neurochemical abnormalities responsible for psychosis. Several lines of evidence also associate schizophrenia with dysfunction of glutamatergic transmission 20 . Indeed, recent preclinical assays in rodents suggest that drugs that activate the metabotropic glutamate 2 receptor (mGlu2) represent potential antipsychotic medications [21] [22] [23] , which is further underscored by some clinical measures 24 . Our previous findings convincingly demonstrate that chronic treatment with the atypical antipsychotic clozapine induces downregulation of mGlu2 expression in mouse frontal cortex 25 -a brain region that is important in cognition and perception, and has been implicated more recently in schizophrenia and antipsychotic responses 17, 19, 25 . Together with the antipsychotic properties of drugs that bind to and activate the mGlu2 receptor, these studies led us to hypothesize that downregulation of mGlu2 expression might restrain the therapeutic effects of atypical antipsychotic drugs.
a r t I C l e S
Here we found that chronic administration of atypical antipsychotic drugs selectively upregulated the expression of HDAC2 in both mouse and human frontal cortex, an effect that was associated with a 5HT2A-dependent regulation of HDAC2 transcriptional activity and increased binding of HDAC2 to the promoter region of the mGlu2 gene. We also found that recruitment of HDAC2 led to a decrease in histone acetylation at the mGlu2 promoter, and that prevention of this mark of transcriptional repression by HDAC inhibitors improved responses to atypical antipsychotic drugs. Together, these data suggest that HDAC2 may be a new therapeutic target to augment the treatment of schizophrenia.
RESULTS

Histone modifications at mGlu2 by chronic antipsychotics
In schizophrenia patients, antipsychotic drugs are administered chronically (weeks to months of sustained drug treatment) 26 . We have previously shown that chronic treatment with clozapine downregulates mGlu2 expression in mice 25 . We found here similar effects with chronic (21-d) clozapine and risperidone, but not haloperidol-a first-generation (or typical) antipsychotic drug-in mouse frontal cortex ( Fig. 1a-d ; see also Supplementary Fig. 1d for the effect of chronic haloperidol on dopamine D2 receptor binding in striatum and Supplementary Fig. 1h for absence of effect of chronic clozapine on mGlu2 expression in thalamus and striatum). Previous work has demonstrated that activation of cortical mGlu2 modulates the cellular and behavioral responses induced by hallucinogenic and antipsychotic 5HT2A ligands 23, 25 . Recent observations also suggest chromatin remodeling in cortical neurons as a mechanism involved in the molecular responses to chronic treatment with antipsychotic drugs [6] [7] [8] . The notable regulation of mGlu2 expression by atypical antipsychotic drugs prompted us to investigate the effect of chronic antipsychotic treatments on the epigenetic status of the mGlu2 promoter in mouse and human frontal cortex.
We quantified several post-translational histone modifications at the promoter region of the mGlu2 gene in mouse frontal cortex using a series of chromatin immunoprecipitation (ChIP) assays. Histone H3 acetylation, which correlates with transcriptional activation 14 , was strongly decreased at the mGlu2 promoter by chronic clozapine and risperidone, but not haloperidol ( Fig. 1e-g ). Earlier studies have also implicated monoaminergic and glutamatergic receptor genes, such as 5HT2A (Htr2a), 5HT2C (Htr2c), dopamine D2 (Drd2) and mGlu3 (Grm3) in psychosis and antipsychotic responses [27] [28] [29] [30] [31] . We found that only clozapine, and neither risperidone nor haloperidol, decreased histone H3 acetylation at the 5HT2A promoter in mouse frontal cortex ( Fig. 1e-g ; see also Fig. 1d and Supplementary Fig. 1h for decreased 5HT2A mRNA expression and Supplementary Fig. 1a -c for decreased density of 5HT2A binding sites). There were no significant changes at the 5HT2C, D2 and mGlu3 promoters. We obtained similar results with histone H4 acetylation (Supplementary Fig. 2a ). Histone H3 methylation at lysine 4 (H3K4me1, H3K4me2 and/or H3K4me3), another marker of gene activation, was not affected by any of the tested chronic antipsychotic treatments at these promoters (Supplementary Fig. 2a) .
We next examined whether histone modifications known to correlate with transcriptional repression were altered by chronic treatment with antipsychotics. Chronic clozapine or risperidone, but not haloperidol, elicited an increase in histone H3 trimethylation at lysine 27 (H3K27me3), a repressive histone modification marker, at the mGlu2 promoter, with no apparent changes at the 5HT2A, 5HT2C, D2 and mGlu3 promoters ( Supplementary  Fig. 2a ). None of the tested chronic treatments increased histone H3 trimethylation at lysine 9 (H3K9me3), another histone modification that correlates with transcriptional repression, at these promoters (Supplementary Fig. 2a ). In addition, we did not detect the d binding in mouse frontal cortex after vehicle or clozapine (a; F 2,95 = 65.34, P < 0.001; n = 4 independent experiments performed in triplicate), risperidone (b; F 2,117 = 166.4, P < 0.001; n = 6 independent experiments performed in triplicate) or haloperidol (c; F 2,116 = 1.29, P > 0.05; n = 6 independent experiments performed in triplicate). Maximum number of binding sites (B max ) for [ 3 H]LY341495 obtained from saturation curves is decreased by chronic clozapine (t = 6.32) and risperidone (t = 6.53) but not haloperidol (t = 0.97; P > 0.05; NS, not significant); two-tailed Student's t-test. **P < 0.01. (d) Expression of 5HT2A (F 3,20 = 5.66, P < 0.01), 5HT2C (F 3,20 = 0.29, P > 0.05), D2 (F 3,20 = 0.31, P > 0.05), mGlu2 (F 3,20 = 6.62, P < 0.01) and mGlu3 (F 3,20 = 0.13, P > 0.05) mRNA in mouse frontal cortex assayed by quantitative reverse transcription (qRT)-PCR (n = 6 mice per group). *P < 0.05; **P < 0.01; Bonferroni's post hoc test of one-way ANOVA. (e-h) Decreased acetylation of histone H3 (H3ac) at the mGlu2 promoter by clozapine (e; t = 2.77) and risperidone (f; t = 5.38), but not by haloperidol (g; t = 1.08) or fluoxetine (h; t = 0.41), in mouse frontal cortex. Decreased acetylation of H3ac at 5HT2A promoter by clozapine (e; t = 2.96). # P < 0.011, two-tailed Student's t-test corrected for multiple null hypotheses by Holm's Bonferroni method. Error bars, s.e.m. npg a r t I C l e S repressive histone modifications induced at the mGlu2 promoter by atypical antipsychotics after subchronic (2-d) treatment with clozapine, risperidone or haloperidol (Supplementary Fig. 2b ). Chronic treatment with the antidepressant fluoxetine did not affect the pattern of histone H3 acetylation or H3K27me3 modification at the promoter regions of the 5HT2A, 5HT2C, D2, mGlu2 or mGlu3 genes ( Fig. 1h and Supplementary Fig. 2c ).
Several reports have suggested that certain histone modifications facilitate the methylation of DNA at specific promoter regions 6 and that atypical antipsychotics activate DNA demethylation in cortical inhibitory interneurons 7 . However, DNA methylation analysis revealed that chronic clozapine did not affect the methylation pattern of the tested CpG sites at the mGlu2 promoter ( Supplementary  Fig. 3 ). Therefore, DNA methylation does not seem to contribute to the repression of the mGlu2 gene.
To further investigate the effect of chronic atypical antipsychotic drugs on the epigenetic modifications of histones at the mGlu2 promoter, we performed ChIP experiments in post-mortem frontal cortex from subjects with schizophrenia and controls. We compared two different groups of subjects with schizophrenia: those either untreated with antipsychotic drugs or treated with atypical antipsychotics. Subjects in each of these two groups were individually matched with control subjects (see Supplementary Table 1 for demographic information). Consistent with our findings in mice, we observed less histone H3 acetylation at the mGlu2 promoter in samples from treated, but not untreated, subjects with schizophrenia ( Fig. 2a,b) . This epigenetic difference at the mGlu2 promoter was found in tissues from each matched pair of subjects with treated schizophrenia and control subjects (Fig. 2c,d ). Histone H3 acetylation was not significantly different at the 5HT2A, 5HT2C or mGlu3 promoters in samples from either treated or untreated subjects with schizophrenia compared to controls (Fig. 2a,b) . We used β 2 -microglobulin (B2M), a constitutively expressed gene in frontal cortex 32 , as an internal control (see also Supplementary Fig. 4a for assays including non-immune immunoglobulin G (IgG) to control for the specificity of ChIP assays in post-mortem human brain).
Upregulation of HDAC2 by chronic atypical antipsychotics These changes in the histone code at the mGlu2 promoter led us to speculate that chronic atypical antipsychotic drugs might regulate the transcription and function of genes associated with histone posttranslational modifications. HDACs are epigenetic regulators that repress gene transcription through the removal of acetyl groups from histone tails. Mammalian HDACs fall into four main classes, with class I and II HDACs receiving the most attention in the CNS 8 . We examined whether treatment with the atypical antipsychotic clozapine altered expression of class I or class II Hdac mRNAs in mouse frontal cortex. Only Hdac2 mRNA levels were significantly increased by chronic clozapine (Fig. 3a) . We next tested the effect of chronic clozapine on HDAC2 protein expression in mouse frontal cortex (Fig. 3) . Expression of HDAC2 protein was elevated upon chronic clozapine as compared to controls (Fig. 3c,e) . HDAC1 protein, another class I HDAC family member 8 , and HDAC4 protein, which has been shown to be highly expressed in neocortical regions 33 , were unaffected (Fig. 3c,e) . Expression of Hdac1, Hdac2 and Hdac4 mRNA was not affected by chronic treatment with chronic haloperidol in mouse frontal cortex (data not shown).
To study the relevance of the effects observed in mice, we examined HDAC1, HDAC2 and HDAC4 protein levels in post-mortem frontal cortex from subjects with schizophrenia untreated or treated with atypical antipsychotics, and from controls (Supplementary Table 1 ).
Equivalently to the higher HDAC2 expression found in mouse frontal cortex by chronic treatment with clozapine, we observed elevated expression of HDAC2, and not HDAC1 or HDAC4, in frontal cortex of subjects with schizophrenia treated with atypical antipsychotics, but not in the untreated group (Fig. 3f-h ).
5-HT 2A -dependent modulation of HDAC2 promoter activity Next we explored the mechanism through which chronic antipsychotics upregulated HDAC2 expression in mouse frontal cortex. The high affinity of clozapine for both the 5HT2A and the dopamine D2 receptor 16, 17 prompted us to consider whether signaling pathways downstream of these receptors may modulate HDAC2 promoter activity. Using promoter-reporter gene constructs in human embryonic kidney cell line HEK293 cells, we examined the impact of 5HT2A-and/or D2-dependent signaling on the transcriptional activity of HDAC2 in tissue culture. Activation of the 5HT2A receptor by the neurotransmitter serotonin resulted in inhibition of HDAC2 promoter activity (Fig. 3i) , and, notably, this effect was reversed by clozapine in a concentration-dependent manner (Fig. 3j) . Neither dopamine nor clozapine affected the promoter activity of HDAC2 in cells expressing the D2 receptor (Fig. 3k ). These data demonstrate that, in vitro in HEK293 cells, clozapine and serotonin differentially modulate HDAC2 promoter activity in a 5HT2A-dependent manner.
However, the overall signal transduction amplification systems present in HEK293 cells and in mouse frontal cortex and the levels of receptor expressed per cell may differ 34 , which could consequently affect to different extents the promoter activity of the HDAC2 gene. We therefore assessed whether the ability of clozapine to enhance the transcriptional activity of Hdac2 in mouse frontal cortex was 5HT2A npg a r t I C l e S dependent. Notably, we found that the upregulation of Hdac2 expression by chronic clozapine observed in wild-type (5HT2A +/+ ) mice (Fig. 3a, c,e) was abolished in 5HT2A null mutant (5HT2A −/− ) mice ( Fig. 3b,d ,e). No other Hdac tested showed regulation by chronic clozapine in 5HT2A −/− mice ( Fig. 3b,d ,e). Together with the experiments in tissue culture (Fig. 3i ,j,k), this work provides mechanistic insight into how chronic atypical antipsychotics lead to elevations in HDAC2 expression in the frontal cortex.
Clozapine upregulates HDAC2 binding to mGlu2 promoter The highly specific effect of chronic atypical antipsychotics on HDAC2 expression in frontal cortex, together with the repressive histone modifications induced at promoter region of the mGlu2 gene ( Figs. 1 and 2 ), led us to examine the role of HDAC2 in regulating the transcriptional activity of the mGlu2 promoter. We first tested the association of HDAC1, HDAC2 and HDAC4 with the promoter regions of 5HT2A, 5HT2C, mGlu2, and mGlu3 genes, including the β-actin (Actb) promoter as internal control. HDAC2 was more enriched than HDAC1 or HDAC4 at the mGlu2 and mGlu3 promoters, whereas we detected no binding at promoter regions of the 5HT2A and 5HT2C genes (Fig. 4a,b) . We next evaluated the effect of chronic clozapine on HDAC2 binding to the mGlu2 and mGlu3 promoters in mouse frontal cortex.
Notably, chronic clozapine significantly increased HDAC2 binding to the mGlu2, and not to the mGlu3, promoter (Fig. 4c) . This did not occur in 5HT2A −/− mice, which further supports 5HT2A-dependent signaling as a modulator of expression and epigenetic function of HDAC2 ( Fig. 4d ; see also Supplementary Fig. 1e -g for absence of effect of chronic atypical antipsychotics on mGlu2 expression in 5HT2A −/− mice, and Supplementary Fig. 2d for absence of effect of chronic atypical antipsychotics on the repressive histone modifications induced at the mGlu2 promoter in 5HT2A −/− mice). Chronic clozapine did not affect binding of HDAC4 to the promoters of mGlu2, mGlu3 and β-actin genes (Fig. 4e) .
We further investigated in cell culture the functional significance of this finding. We first tested whether HDAC2 is associated with the mGlu2 promoter in HEK293 cells. ChIP analysis revealed that HDAC2 bound to the mGlu2 promoter, as it was efficiently immunoprecipitated by antibody to Flag in cells overexpressing Flag-tagged HDAC2 (Fig. 4f) . Next we determined by promoter reporter assay the effect of HDAC2 on mGlu2 promoter activity. Overexpression of HDAC2 (but not of the deacetylase activity-deficient mutant HDAC2-H141A) impaired mGlu2 promoter function in a concentration-dependent manner, which demonstrated that HDAC2 negatively regulated mGlu2 expression in cultured cells ( a r t I C l e S and Flag-HDAC2-H141A in HEK293 cells). These findings provide evidence that HDAC2 is critical for regulating transcriptional activation of the mGlu2 promoter. Taken together, our findings indicate that chronic atypical antipsychotic drugs upregulate HDAC2 promoter activity and expression through an epigenetic mechanism that involves 5HT2A-dependent signaling, which leads to a higher binding of HDAC2 to and negative regulation of the mGlu2 promoter in mouse frontal cortex.
HDAC2 overexpression induces schizophrenia-like behavior
To further establish a causal link between changes in HDAC2 expression and transcriptional repression of the mGlu2 promoter, we overexpressed HDAC2 in mouse frontal cortex to examine whether this manipulation would regulate mGlu2 expression and its behavioral function. Mice received intra-frontal cortex injections of bicistronic herpes simplex 2 viral particles (HSV-2) expressing green fluorescent protein (GFP) and Flag-HDAC2, or GFP alone. First, we confirmed that the virus overexpressed Flag-HDAC2 in mouse frontal cortex ( Fig. 5a and Supplementary Fig. 5b) . Notably, such overexpression of HDAC2 decreased mGlu2 mRNA, but not 5HT2A, 5HT2C, mGlu3 or β-actin mRNAs, in this brain region (Fig. 5b) . The absence of significant effect of HDAC2 overexpression on the transcription of the mGlu3 gene may be due to the predominant location of the mGlu3 receptor in cortical presynaptic terminals and glial cells 17, 35 . Previous findings demonstrate that activation of mGlu2 attenuates spontaneous excitatory postsynaptic currents (sEPSC) induced by 5HT2A agonists, including 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), in cortical pyramidal neurons [36] [37] [38] . To determine whether overexpression of HDAC2 influences the functional responses mediated by mGlu2, we examined the inhibitory effects of the mGlu2/3 agonist LY379268 on the DOI-induced (5HT2A-dependent) sEPSC in cortical slices prepared from mice injected with HSV-HDAC2, and from their HSV-GFP counterparts. As expected, activation of the 5HT2A receptor by DOI induced an increase in sEPSC, an effect that was reduced by LY379268 in animals overexpressing GFP alone as well as in uninfected control neurons (Fig. 5c,d and Supplementary  Fig. 5c ). Further, and notably, HDAC2 overexpression decreased the inhibitory effect of LY379268, as compared to the reduction obtained in uninfected GFP-negative and HSV-GFP cortical neurons (Fig. 5c,d and Supplementary Fig. 5c ). Together, the reduction of mGlu2 expression (Fig. 5b) and the reduction in the efficacy of the mGlu2/3 agonist on 5HT2A-mediated sEPSC consistently support the idea that HSV-HDAC2 negatively regulates mGlu2 transcription, which limits the functional antagonism between mGlu2 and 5HT2A receptors in mouse frontal cortex.
To gain further insight into these phenomena, we next examined whether this manipulation would affect behavioral responses that require 5HT2A-and/or mGlu2-mediated signaling pathways. We have previously demonstrated that the head-twitch murine behavioral response is reliably and robustly elicited by hallucinogenic drugs such as psilocybin, mescaline and LSD, and is absent in 5HT2A −/− mice 19 . Notably, we found here that the head-twitch response induced by a low dose of the hallucinogenic drug DOI (0.5 mg per kilogram body weight) was significantly greater in frontal cortex of mice overexpressing HDAC2, but not HDAC1 or HDAC4, than in frontal cortex of (Fig. 5e) . As activation of the mGlu2 receptor abolishes the head-twitch response induced by hallucinogens 25, 36 , these findings correlate with the lower expression of mGlu2 in mice overexpressing HDAC2 in frontal cortex.
To complement the behavioral findings obtained with hallucinogens, we next investigated the effects of HDAC2 overexpression in frontal cortex on behavioral responses induced by the potent and selective noncompetitive NMDA receptor antagonist MK801 (dizocilpine). MK801 and other noncompetitive NMDA receptor antagonists evoke in healthy humans psychotic and other symptoms resembling aspects of schizophrenia 39 . Previous findings demonstrate that activation of mGlu2, and not mGlu3, by the mGlu2 and mGlu3 receptor agonist LY379268 reduces the locomotor hyperactivity induced by MK801 (ref. 22) . We found that neither HSV-GFP nor HSV-HDAC2 affected the locomotor activity induced by MK801 ( Fig. 5f  and Supplementary Fig. 5d ). In notable contrast, however, HDAC2 overexpression diminished the ability of LY379268 (8 mg kg −1 ), the mGlu2 and mGlu3 agonist, to reduce the MK801-dependent locomotor response. Overexpression of HDAC1 or HDAC4 in frontal cortex did not affect the locomotor behavioral effects of MK801 or LY379268 ( Fig. 5f and Supplementary Fig. 5d ). Spontaneous locomotor activity and time spent in the center of an arena (protocols used in the evaluation of anxiety; see ref. 40) were comparable among mice that received intra-frontal cortex injections of HSV-2 vectors expressing HDAC1, HDAC2, HDAC4, and/or GFP (Supplementary Fig. 5e ).
Deficits in the filtering or gating sensory and cognitive information have also been theorized to be core features of schizophrenia. Prepulse inhibition (PPI) is a measure of sensorimotor gating that refers to the reduction in the startle response produced by a low-intensity nonstartling stimulus (the prepulse) presented shortly before the startle stimulus 41 . Patients with schizophrenia exhibit diminished PPI of the acoustic startle reflex 42 , which represents one operational measure of sensorimotor gating and cognitive impairment. We compared the effects of LY379268 on the impaired PPI response induced by MK801 in mice overexpressing HDAC2 and controls. The MK801-dependent deficit in the PPI test was not affected by virally mediated overexpression of HDAC2 (Fig. 5g) . Consistent with previous findings in rodents and healthy human subjects 41 , LY379268 prevented the PPI deficits evoked by MK801 in HSV-GFP control mice. Notably, the behavioral effects of LY379268 on the MK801-dependent PPI deficits were significantly reduced in mice overexpressing HDAC2 (Fig. 5g) . These data suggest that HDAC2 negatively regulates sensorimotor gating of the startle reflex.
Patients with schizophrenia also demonstrate impairments on a variety of working memory tests. Working memory requires the ability to form memory traces over a brief time period in order to manipulate this information to guide a goal-oriented behavior 40 . In rodents, working memory can be reliably assessed in a T-maze using a discrete-trial delayed spatial alternation task. We found that MK801 impaired choice accuracy in the T-maze delayed alternation npg a r t I C l e S task, an effect that was reversed by LY379268 in HSV-GFP control mice ( Fig. 5h and Supplementary Fig. 5g ). In contrast, the effect of LY379268 on MK801-induced impairment in the T-maze was reduced in mice overexpressing HDAC2 in frontal cortex, as measured by the percentage of entries into the correct arms ( Fig. 5h and Supplementary Fig. 5g ; see also Supplementary Fig. 5f for T-maze task in uninfected control mice). Taken together, our findings indicate that increased expression of HDAC2 in mouse frontal cortex results in behaviors that are associated with impaired mGlu2 function.
SAHA improves antipsychotic-like effects of clozapine
Recent preclinical and clinical results suggest that drugs that activate the mGlu2 receptor may represent a new approach for the treatment of schizophrenia [21] [22] [23] [24] . Our results thus far indicate that chronic atypical antipsychotics selectively upregulate the expression of HDAC2 in frontal cortex, which precisely parallels the decreased acetylation at the promoter region of the mGlu2 gene in both mouse and human. These findings led us to hypothesize that prevention of this repressive histone modification at the mGlu2 promoter with HDAC inhibitors would augment the therapeutic-like behavioral responses induced in mice by atypical antipsychotic drugs.
To directly examine this possibility, we first investigated the effects of two HDAC inhibitors, suberoylanilide hydroxamic acid (SAHA) and MS-275, which are selective inhibitors of class I and II HDACs and have been shown to modulate mGlu2 expression in mammalian CNS 43 . Mice were stereotactically injected in the frontal cortex with a single dose of SAHA, MS-275 or vehicle and were analyzed 24 h later. Both SAHA and MS-275 increased mGlu2 and mGlu3 mRNA expression, whereas they did not affect 5HT2A and 5HT2C mRNA expression (Supplementary Fig. 4b ). ChIP assays showed that histone H3 acetylation was increased at the promoter regions of the mGlu2 and mGlu3 genes by local administration of SAHA or MS-275 in frontal cortex (Supplementary Fig. 4c ; see also Supplementary Fig. 4d ,e for promoter assay and ChIP experiments with SAHA and MS-275, and another HDAC inhibitor trichostatin A in tissue culture). These data indicate that HDAC inhibitors stimulate mGlu2 promoter activity in vitro as well as in vivo in mouse frontal cortex.
Next, we directly compared the effects of chronic SAHA treatment with that of clozapine on the expression of mGlu2. We tested the effects of SAHA because MS-275 does not effectively penetrate the blood brain barrier when given systemically 44 , and our data validate the ability of chronic intraperitoneal administration of SAHA to increase histone (Supplementary Fig. 4f,g ). As above ( Fig. 1 and  Supplementary Fig. 1 ), chronic clozapine downregulated the expression of 5HT2A and mGlu2, but not 5HT2C and mGlu3, in mouse frontal cortex (Fig. 6a-e) . Notably, although chronic SAHA had no effect on 5HT2A (Fig. 6a,b,e) , it increased the expression of mGlu2 and mGlu3 and, more importantly, reversed the downregulation of mGlu2 caused by chronic clozapine (Fig. 6c-e) . Such transcriptional regulation of the mGlu2 and mGlu3 genes, and the lack of regulation of the 5HT2A gene, was tightly correlated with active binding of acetyl-histone H3 at their respective promoters (Fig. 6f) . Together, these data show that chronic SAHA increases the expression of mGlu2 and mGlu3, and that adjunctive SAHA treatment prevents the repressive epigenetic changes induced at the mGlu2 promoter by chronic clozapine.
To examine the therapeutic-like relevance of our findings, we next investigated whether abolition by SAHA of the clozapine-induced histone modifications at the mGlu2 promoter in frontal cortex is associated with alterations in behavioral responses induced by antipsychotic drugs. We treated mice with clozapine, risperidone, haloperidol or vehicle chronically (21 d) or subchronically (2 d) before assessing the head-twitch response to the hallucinogenic drug DOI 1 d after the last injection. The head-twitch response induced by DOI (2 mg/kg) was decreased by chronic, but not subchronic, clozapine or risperidone ( Supplementary Fig. 6a,b) . Chronic haloperidol did not affect the head-twitch response induced by DOI (Supplementary Fig. 6a) . We also observed that chronic SAHA diminished the head-twitch response induced by DOI to a similar extent to that found after chronic clozapine (Fig. 6g) . Furthermore, chronic SAHA potentiated this antipsychotic-like effect of chronic clozapine (Fig. 6g) , a lasting behavioral effect that was even further accentuated 5 d after the last chronic injection (Supplementary Fig. 6c) .
We next compared the effects of chronic SAHA on the behavioral response induced by the psychotomimetic drug MK801. We found that neither a low dose of LY379268 (1.5 mg kg −1 ) alone nor chronic SAHA alone influenced the locomotor response induced by MK801 (Fig. 6h  and Supplementary Fig. 6e) . However, the MK801-dependent locomotor hyperactivity was attenuated in mice that received both chronic SAHA and acute LY379268 (Fig. 6h and Supplementary Fig. 6e ; see also Supplementary Fig. 6d for selection of a low dose of LY379268 that by itself does not affect the locomotor activity induced by MK801). We also compared the effects of chronic SAHA on the impaired PPI response induced by MK801. As shown above (Fig. 5f) , MK801 induced PPI deficits in control mice, an effect that was reversed by LY379268 (Fig. 6i) . Notably, we also found that chronic treatment with SAHA prevented the PPI deficits evoked by MK801, an effect that was similar to that induced by LY379268 (Fig. 6i) . Together, these findings demonstrate that chronic treatment with the HDAC inhibitor SAHA enhances the behavioral effects induced by LY379268 using three different mouse models. Recent pathophysiological studies highlight the role of altered brain connectivity and synaptic plasticity in schizophrenia 2 . Our data do not exclude the possibility that HDAC2-dependent alterations in the expression of other genes, each of which has previously been implicated in cognitive function and synaptic plasticity 45, 46 , also affect the behavioral responses induced by chronic treatment with SAHA (Supplementary Fig. 4h ).
DISCUSSION
Chromatin remodeling has been implicated in the neurochemical mechanisms by which antipsychotic drugs achieve their clinical efficacy 8, 47 . Although these findings provide compelling evidence for the involvement of epigenetic processes in the molecular events associated with the treatment of schizophrenia, they do not exclude the possibility of compensatory mechanisms that may emerge in response to chronic antipsychotic drug exposure and ultimately restrain their therapeutic effects. Compensatory mechanisms are seen as negative correlations between processes that are pivotal for system function 48 . Within an individual neuron or individual animal, alterations in one parameter may produce minor changes in the state of the system if there are mechanisms that cause adjustments in another parameter to compensate for the first change. Here we have demonstrated that chronic treatment with atypical antipsychotic drugs markedly decreased the density of 5HT2A binding sites in mouse frontal cortex, which led to repressive histone modifications at the promoter region of the mGlu2 gene. Furthermore, our data reveal that HDAC2 is critical in mediating these 5HT2A-dependent repressive epigenetic modifications at the mGlu2 promoter in mouse and human frontal cortex. We found that chronic administration of atypical antipsychotic drugs selectively upregulated HDAC2 expression and binding to the mGlu2 promoter, an effect that was associated with the regulation of HDAC2 promoter transcriptional function by activation of the 5HT2A receptor. We then demonstrated that such overexpression of HDAC2 in frontal cortex was sufficient to downregulate mGlu2 expression and its physiological inhibitory effects, which exacerbated schizophrenialike behavior. Activation of mGlu2 is well known to repress cellular, electrophysiological and behavioral responses that require the 5HT2A receptor 20 . Similarly, drugs that activate the mGlu2 receptor have potential for the treatment of schizophrenia, whereas 5HT2A agonists, such as hallucinogenic compounds, result in the opposite effect. Taken together, these data suggest that the decreased density of 5HT2A binding sites produced by chronic treatment with atypical antipsychotic drugs results in a compensatory mechanism of repressive chromatin structure at the promoter region of the mGlu2 gene, with consequently less inhibitory effects of the mGlu2 receptor on 5HT2A-regulated pathways and behaviors.
We also observed that adjunctive SAHA abolished the repressive histone modifications induced at the mGlu2 promoter by chronic atypical antipsychotics, which augmented the behavioral effects induced by atypical and glutamate antipsychotics. Overall, our findings support the hypothesis that compensatory epigenetic events at the mGlu2 promoter may be responsible for the high incidence of patients who do not benefit from conventional therapy with atypical antipsychotic drugs, and they provide a biochemical explanation for the clinical association of pharmacological inhibition of HDACs with improved schizophrenia treatment (Supplementary Fig. 7) .
Previous studies from our laboratory have shown that 5HT2A and mGlu2 interact through specific transmembrane domains to form a G protein-coupled receptor (GPCR) heterocomplex in mouse and human frontal cortex 25 . The signaling properties of this receptor heterocomplex have been proposed to be necessary for therapeutic-like effects of atypical antipsychotic drugs 23 . We found here that chronic atypical antipsychotic drugs induced 5HT2A-dependent repressive histone modifications at the mGlu2 promoter in frontal cortex, which is consistent with previous reports describing effects of long-term treatment with 5HT2A agonists on behavioral responses that require the mGlu2 receptor 36, 37 . Further work will be directed to assessing the relative contributions of these epigenetic factors to the modulation of expression of 5HT2A and mGlu2 as a GPCR heterocomplex that may balance the response to ligand inputs in cortical pyramidal neurons.
Clozapine is the only antipsychotic drug with proven superior efficacy in treatment-resistant schizophrenia 4 . We found that both clozapine and risperidone, but not haloperidol, decreased the density of 5HT2A binding sites in mouse frontal cortex. Similar findings on npg a r t I C l e S 5HT2A receptor binding have been reported in post-mortem human brain from subjects with treated schizophrenia 25, 49 . These results suggest that the 5HT2A receptor is involved in treating the psychotic symptoms of schizophrenia and that downregulation of 5HT2A receptor binding sites by chronic atypical antipsychotic drugs may be one of the mechanisms underlying their therapeutic effects. Notably, only chronic clozapine induced changes in histone acetylation at the 5HT2A promoter that correlated with its transcriptional repression. Although further investigation is needed to understand the mechanisms and consequences of this finding, it is tempting to speculate that these histone modifications at the promoter of the 5HT2A gene may account for the enhanced antipsychotic properties of clozapine. Further work is also needed to determine the molecular mechanisms responsible for downregulation of 5HT2A mRNA expression in subcortical regions by chronic treatment with clozapine.
A notable finding of the current study is that chronic treatment with clozapine upregulated HDAC2 in mouse frontal cortex. In concordance with the effects of clozapine in murine models, the expression of HDAC2 was elevated in post-mortem frontal cortex of subjects with schizophrenia treated with atypical antipsychotic drugs. As we detected no alteration in untreated subjects with schizophrenia, these results suggest that dysregulation of HDAC2 expression represents a consequence of antipsychotic drug medication, and not a biochemical marker of schizophrenia in post-mortem human brain. This is a noteworthy observation because virally mediated overexpression of HDAC2 in mouse frontal cortex induced behavioral alterations that replicate psychotic symptoms and cognitive impairments in patients with schizophrenia. Notably, clinical studies indicate that deficits in attention and memory function, cognitive impairments that represent core features of schizophrenia 1, 2 , are exacerbated by treatment with atypical antipsychotic drugs 50 . Together, these findings suggest that the 5HT2A-dependent upregulation of HDAC2 and repressive histone modifications at the mGlu2 promoter might be related to the negative modulation of cognitive processes by chronic treatment with atypical antipsychotic drugs.
The ultimate goal of understanding the pathophysiology of schizophrenia is to develop therapeutic strategies that improve or restore normal brain activity and, ultimately, ameliorate the associated deficits in sensory processing, perception and memory function. The functions of HDAC2 described here have implications for the molecular basis of the limited response to treatment with atypical antipsychotics. We propose that atypical antipsychotic drugs induce a selective upregulation of HDAC2 in frontal cortex of individuals with schizophrenia, which alters the chromatin state of the mGlu2 promoter and thereby limits the therapeutic effects of these agents. Identification of the epigenetic mechanisms through which administration of HDAC inhibitors potentiates the biochemical and behavioral responses to atypical antipsychotics will help in discovering more effective treatments to improve the clinical efficacy of the available antipsychotic medications. Specifically, our findings encourage the development and testing of HDAC2-selective inhibitors for schizophrenia.
METHODS
Methods and any associated references are available in the online version of the paper. Immunoprecipitation of native chromatin in post-mortem human brain. Postmortem tissue samples (50 mg) were homogenized with douncing buffer (4 mM MgCl 2 , 1 mM CaCl 2 , and 10 mM Tris-HCl; pH 7.5) and then incubated with 2 U/ml of micrococcal nuclease (MNase; Sigma-Aldrich) for 10 min at 37 °C. The MNase activity was stopped by adding EDTA to a final concentration of 10 mM. The lysate was diluted by adding tenfold volume excess of hypotonic lysis buffer (0.1 mM benzamidine, 0.1 mM phenylmethylsulfonylfluoride (PMSF),1.5 mM 1,4-dithio-dl-threitol (DTT), and 0.2 mM EDTA; pH 8.0) and then incubated on ice for 1 h. The lysate was centrifuged at 3000 × g to remove insoluble material. The soluble chromatin was diluted by adding tenfold volume excess of incubation buffer (50 mM EDTA, 500 mM NaCl, and 200 mM Tris-HCl; pH 7.5). Immunoprecipitation and DNA purification was performed as described above for the ChIP assay in mouse frontal cortex (see Supplementary Table 2 for primer pair sequences). dnA methylation assay. DNA methylation assay was performed using the NonOrganic DNA Extraction Kit (Millipore) according to the manufacturer's instructions. Genomic DNA was isolated from mouse brain frontal cortex and liver tissue samples using the Non-Organic DNA Extraction Kit (Millipore) according to the manufacturer's instructions, and subjected to bisulfite modification to convert all non-methylated cytosines into thymidines. For sodium bisulfite treatment, the CpGenomie Fast DNA Modification Kit (Millipore) was used according to the manufacturer's instructions. Modified DNA was then amplified by PCR using bisulfite-treated DNA specific primer sets 5′-GGTATTAAGGGTTAA TTTTATTTGG-3′ and 5′-ACACTATAAACAACTCCAAACCCTAC-3′; and 5′-TGAGAGGTTGAGATAAAGATAGAGATATAG-3′ and 5′-CCAAATAAAA TTAACCCTTAATACC-3′, which did not include any CpG sites where possible methylation could be present. The PCR products were cloned using TOPO-TA cloning kit (Invitrogen) and transformed into TOP10 competent cells. Nine to 12 different colonies from each DNA amplification reaction were then analyzed for possible methylated CpG sites using direct sequencing from the TOPO plasmids containing the insert. . Incubation with the secondary antibody (1:5,000) coupled to peroxidase (Amersham Biosciences NA931V/AD and NA934V/AC) was performed at room temperature for 90 min, followed by repeated washing with TBST. Immunoreactive proteins were visualized with enhanced chemiluminescence (Thermo Scientific) according to the manufacturer's instructions. Western blot experiments in mouse brain samples were quantified by densitometry using the NIH Image 1.62 software. Nuclear-cytoplasmic fractionation was performed using NE-PER extraction kit (Thermo Scientific), following manufacturer's instructions (see Supplementary Fig. 4g ). Western blot experiments in post-mortem human brain samples were analyzed with the Odyssey infrared imaging system (LI-COR Biosciences). The membranes were incubated with secondary antibodies (Alexa 680 Fluor goat anti-mouse, Invitrogen A21057, 1:1,500; Alexa 680 Fluor goat anti-rabbit, Invitrogen A21076, 1:1,500; Alexa 680 Fluor donkey anti-goat, Invitrogen A21084, 1:2,500; IRDye 800 donkey anti-mouse, Rockland Immunochemicals 610-732-002, 1:10,000; IRDye 800 goat anti-rabbit, Rockland Immunochemicals 611-132-002, 1:10,000). The membranes were then scanned on an Odyssey infrared imaging system, and images were acquired and analyzed according to manufacturer's instructions.
Virally mediated gene transfer. HDAC1, HDAC2 and HDAC4 cDNAs were subcloned into a published bicistronic HSV-GFP virus vector (see above) 51 , and viral particles were then packaged as described before 51 . HSV-HDAC1, HSV-HDAC2, HSV-HDAC4, or control HSV-GFP was injected into the frontal cortex by stereotaxic surgery according to standard methods 51 . Mice were anesthetized with a combination of ketamine (100 mg/kg) and xylazine (10 mg/kg) during the surgery. The virus was delivered bilaterally with a Hamilton syringe at a rate of 0.1 µl/min for a total volume of 0.5 µl on each side. The following coordinates were used: +1.6 mm rostral-caudal, −2.4 mm dorsal-ventral, +2.6 mm mediallateral from bregma (relative to dura) with a 10° lateral angle. The coordinates were taken according to a published atlas of the 129/Sv mouse strain 54 . The Nissl staining of the coronal brain slice was taken from the mouse brain atlas with author's permission (Fig. 5a) 54 . All experiments were performed 3-4 d after the viral infection, when transgene expression is maximal 51 . Virally mediated HDAC1, HDAC2 and HDAC3 overexpression levels in frontal cortex were confirmed by western blotting and quantitative real-time PCR ( Supplementary  Fig. 5b and data not shown).
Immunohistochemistry.
Immunohistochemistry experiments were performed as previously reported 23 . GFP immunoreactivity was assayed by using a polyclonal antibody (Santa Cruz sc-8334; 1:100) and Alexa 488 dye-conjugated antirabbit antibody (1:500).
electrophysiology. Whole-cell recordings were obtained from deep layer neurons of the frontal cortex in acute brain slices from 129S6/Sv mice that had been stereotaxically injected into the frontal cortex with HSV-GFP or HSV-HDAC2 (see virally mediated gene transfer above). The preparation of acute brain slices of the frontal cortex and recordings from the frontal cortex were performed as described previously 57 . Briefly, the artificial cerebrospinal fluid (aCSF) contained the following: 128 mM NaCl, 3 mM KCl, 1.25 mM NaH 2 PO 4 , 10 mM D-glucose, 24 mM NaHCO3, 2 mM CaCl 2 , and 2 mM MgSO 4 ; oxygenated with 95% O 2 and 5% CO 2 (pH 7.35, 295-305 mOsm). Sucrose aCSF was derived by fully replacing NaCl with 254 mM sucrose in aCSF, and used during the slice cutting. Patch pipettes (3-5 MΩ) for whole-cell voltage clamp recordings were filled with an internal solution containing the following: 115 mM potassium gluconate, 20 mM KCl, 1.5 mM MgCl 2 , 10 mM phosphocreatine, 10 mM HEPES, 2 mM Mg-ATP, and 0.5 mM GTP (pH 7.2, 285 mOsm). The experiments were carried out at 30 °C. GFP-positive cells were visualized with an upright fluorescence microscope using infrared differential interference contrast illumination and identified by their pyramidal shape and size and prominent apical dendrite in the frontal cortex. The resting membrane potential and spontaneous EPSCs were recorded in voltage clamp mode, holding −70 mV using an amplifier Multiclamp 700B (Molecular Devices). Data acquisition was acquired with pClamp 10. Series resistance was monitored throughout experiments that were terminated whenever significant changes (>20%) in series resistance occurred. DOI and LY379268 were kept as concentrated stocks and diluted in aCSF immediately before experiments. After 2 min of stable baseline recording, DOI (5 µM) was applied for 2-4 min and subsequently DOI (5 µM) and LY379268 (1 µM) were applied for 2-4 min. These concentrations were chosen according to previous findings 38 . The frequency and npg
